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ABSTRACT 23 
Salmonid alphavirus (SAV) causes pancreas disease (PD) in Atlantic salmon (Salmo salar L.) 24 
and disease outbreaks are mainly detected after seawater transfer. The influence of the 25 
smoltification process on the immune responses, specifically the adaptive response of Atlantic 26 
salmon after SAV infection, is not fully understood. In this study, Atlantic salmon post-smolts 27 
were infected by either bath immersion (BI) or intramuscular injection (IM) with SAV subtype 28 
3, 2 weeks (Phase A) or 9 weeks (Phase B) after seawater transfer. The transcript levels of 29 
genes related to cellular, humoral and inflammatory responses were evaluated on head kidney 30 
samples collected at 3, 7, 14, 21, and 28 days post-infection (dpi). Corresponding negative 31 
control groups (CT) were established accordingly. Significant differences were found between 32 
both phases and between the IM and BI groups. The anti-inflammatory cytokine IL-10 was up-33 
regulated in Phase A at a higher level than in Phase B. High mRNA levels of the genes RIG-1, 34 
SOCS1 and STAT1 were observed in all groups except the BI-B group (BI-Phase B). 35 
Moreover, the IM-B group showed a higher regulation of genes related to cellular responses, 36 
such as CD40, MHCII, and IL-15, that indicated the activation of a strong cell-mediated 37 
immune response. CD40 mRNA levels were elevated one week earlier in the BI-B group than 38 
in the BI-A group (BI-Phase A). A significant up-regulation of IgM and IgT genes was seen in 39 
both IM groups, but the presence of neutralizing antibodies to SAV was detected only in Phase 40 
B fish at 21 and 28 dpi. In addition, we found differences in the basal levels of some of the 41 
analysed genes between non-infected control groups of both phases. Findings suggest that 42 
Atlantic salmon post-smolts adapted for a longer time to seawater before they come into contact 43 
with SAV, developed a stronger humoral and cell-mediated immune response during a SAV 44 
infection. 45 
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1. Introduction 50 
Pancreas disease (PD) is a systemic disease characterized by inflammation and cellular necrosis 51 
in exocrine pancreas and subsequent severe cardiac and skeletal myopathies, which results in 52 
high morbidity and mortality of farmed Atlantic salmon (Salmo salar) [1]. Salmonid alphavirus 53 
(SAV), a single-stranded, positive-sense RNA virus of the family Togaviridae, is the 54 
aetiological agent of PD. Six geographically distributed subtypes of SAV have been described 55 
on the basis of partial sequences of the E2 and nsP3 genes [2]. PD has been described in 56 
Atlantic salmon farms in Scotland, Norway, Ireland, France, Spain, and North America [3]. PD 57 
outbreaks in south-western Norway are mainly associated with Salmonid alphavirus subtype 3 58 
(SAV3), which can be spread horizontally between neighboring salmon farms [4,5].  59 
Atlantic salmon aquaculture is normally carried out in two phases: firstly, in land-based 60 
hatcheries where smolts are produced in freshwater tanks using flow-through and re-circulation 61 
systems; and later in an on-growing phase in seawater cages until harvest [6]. It is during the 62 
seawater phase that the farmed Atlantic salmon are most vulnerable to infection from diseases 63 
and parasites partly due to less possibility of controlling the culture conditions. For instance, 64 
natural outbreaks of PD in Atlantic salmon have only been reported in the seawater phase [7] 65 
and therefore PD outbreaks and higher losses are reported in the months after seawater transfer 66 
(SWT). It is known that smoltification and the initial period following seawater transfer is a 67 
time of high energy requirement due to the necessary physiological changes to adapt to 68 
seawater. The smoltification process (also known as Parr-Smolt transformation) is a series of 69 
physiological, morphological and behavioral changes [8,9]. Moreover, immune suppression 70 
characterized by a decrease of total white blood cells and circulating lymphocytes, a decrease 71 
of plasma lysozyme activity, total serum immunoglobulin (Ig) M and total serum protein, and 72 
a down-regulation of some immune genes has been described during smoltification [9-12]. 73 
These data suggest that Atlantic salmon in the process of smoltification and in the post-smolt 74 
period may be especially vulnerable to infectious diseases. A link between smoltification and 75 
susceptibility to Infectious Salmon Anemia Virus (ISAV) was proposed by Glover et al., 2006 76 
[13]. Despite the use of vaccines, the PD challenges in salmon farms persist, but few studies 77 
have evaluated immune responses of Atlantic salmon to PD a few weeks after seawater transfer.   78 
Previous studies employing injection or cohabitation challenge models have demonstrated a 79 
high level of expression of IFN-γ, two IFN-γ responsive genes, and TCR-β genes, suggesting 80 
a sustained acquired immune response in the skeletal muscle [14]. Moreover, a rapid activation 81 
of MHC I and II responses during the early stages of SAV subtype 1 infection have been 82 
reported [15]. Enhanced expression of T cell-related genes such as, T cell co-receptors CD4-1 83 
and CD8α, and TCR-β, as well as MHCII, normally expressed only on antigen-presenting cells, 84 
have been detected during the later stages of SAV3 infection [16,17,14]. 85 
We have established a bath challenge model based on the viral shedding capacity of Atlantic 86 
salmon experimentally injected with SAV. When used in a bath challenge of naïve fish this 87 
SAV3 containing water mimics the natural exposure to water-borne virus. Compared to 88 
cohabitation challenge, a bath challenge model has the advantage of limiting the infection time 89 
to a small window which is useful when studying the time frame of the subsequent immune 90 
responses. The susceptibility of Atlantic salmon post-smolts at 2 and 9 weeks post seawater 91 
transfer (wpt) to SAV3 by comparing fish infected via the bath challenge (BI) model and by 92 
intramuscular (i.m.) injection (IM) has been reported [18]. In addition, we have studied the 93 
immune-related gene regulation of some antiviral immune genes and genes involved in the 94 
pathways leading to interferon (IFN) regulation and the production of ISGs. Smolts fully 95 
acclimatized to seawater showed an increased innate immune response to SAV infection and a 96 
higher basal abundance of several innate immune genes relative to the smolts that were infected 97 
shortly after seawater transfer [19].  98 
In the present work, we have focused on analysing transcript levels of genes directly or 99 
indirectly involved in adaptive responses, including genes that express cell surface 100 
receptors/markers, in Atlantic salmon post-smolts transferred to seawater seven weeks apart 101 
and then infected with SAV3 by BI or IM. The obtained data will give a more comprehensive 102 
understanding of the factors determining survival of salmon suffering from pancreas disease 103 
after seawater transfer and the associated immunological events.  104 
 105 
2. Materials and Methods 106 
2.1 Experimental design, tissue collection, and RNA extraction  107 
Atlantic salmon post-smolts from the same batch of fish (Aquagen strain) were challenged with 108 
SAV3 either 2 (Phase A, average weight of 41g) or 9 (Phase B, average weight of 89 g) weeks 109 
after seawater transfer (oxygen saturation of >85 %; 12 °C; salinity 34.5‰). Na+, K+-ATPase 110 
(NKA) enzyme activity was evaluated in the gills of fish from Phase A and acceptable NKA 111 
activity was observed, and thus this was deemed to have no influence on SAV infection [18]. 112 
NKA levels were not evaluated in fish from Phase B because both groups belonged to the same 113 
production batch and after 9 weeks, the fish appeared well adapted to seawater.  114 
The experimental setup consisted of three groups: negative control (CT); intramuscular 115 
injection (IM); or bath immersion (BI) and each of these groups were in triplicate tanks with 116 
65 fish per tank (Fig. 1A). Fish in the IM group were infected with 104 TCID50 SAV3 117 
propagated in Chum salmon heart-1 (CHH-1) cells [20] and quantified by end-point dilution 118 
assay (TCID50) [21]. Fish in the BI group were bath immersed for 6 h in seawater containing 119 
SAV3, which was shed by shedder fish injected with 104 TCID50 SAV3/fish one week before 120 
the experiment started. The bath immersion dose was estimated by a one-step RT-qPCR assay 121 
of filtered/concentrated shedder tank water, which resulted in an average Ct value of 28 and 34 122 
in Phases A and B, respectively [18]. Infected groups from Phase A were named IM-A and BI-123 
A, and infected groups from Phase B were named IM-B and BI-B. Fish belonging to the control 124 
group from Phase A (CT-A) and from Phase B (CT-B) were injected with supernatant of non-125 
infected cultures of CHH-1 cells. The SAV3 isolate prepared for use in this experiment was 126 
later found to be contaminated with low levels of infectious pancreatic necrosis virus (IPNV). 127 
However, compared with the SAV3, the level of IPNV was so low that it is unlikely to have 128 
caused any discernable effect on the interpretation on the immune gene regulation evaluated 129 
post-infection. In fact, anterior kidney samples from the BI-A group were IPNV negative, and 130 
only 6 fish in the IM-A group and 4 fish in the IM-B group were IPNV positive, with very low 131 
virus loads (Cts all >36) [22]. Before handling, the fish were bath anaesthetized with a mixture 132 
of Metomidate (10 mg L−1) and Benzocaine (60 mg L−1), and before sampling, fish were killed 133 
employing Metomidate and a higher dose of Benzocaine (160 mg L-1). The animal care and 134 
experimental setup were performed in accordance with the established guidelines and approved 135 
by the Norwegian Animal Research Authority (ID: 5651). Further information on experimental 136 
procedures, fish, and virus have been published previously [18].  137 
 138 
Total RNA from head kidney tissue samples described in this study were previously used to 139 
study innate immune gene responses [23,19]. Briefly, head kidney tissue samples were 140 
collected from fish in each treatment group and frozen in liquid nitrogen at 3, 7, 14, 21, and 28 141 
days post-infection (dpi). Total RNA was extracted using an iPrep™ PureLink® Total RNA 142 
Kit (Invitrogen, USA.) with TRIzol® reagent (Ambion) and following the manufacturer’s 143 
instructions. RNA concentration was measured using a Nanodrop ND-1000. Five percent of 144 
the RNA samples from tissues were randomly chosen and checked for integrity on a 145 
Bioanalyser (Agilent Instruments), resulting in RINs of ≥ 9 for all samples tested. 146 
 147 
2.2 cDNA synthesis and quantitative PCR (RT-qPCR) 148 
qScript™ SuperMix (Quanta Biosciences) was used to transcribe cDNA from 1 µg head kidney 149 
total RNA in a 20 µl reaction including priming with both random hexamers and Oligo-dT as 150 
described in the manufacturer's instructions. The cDNA was diluted 1:10 with AMRESCO’s 151 
sterile, Nuclease-free water (VWR) as this was previously demonstrated to be an optimal 152 
dilution for the analysis performed in this study. Assays for CD40, IgM and IgT, SOCS1, CD4-153 
1, CD8α, Retinoic-acid-inducible protein 1 (RIG-1), Nuclear factor kappa-light-chain-154 
enhancer of activated B cells (NFκB), four Interleukins (IL), and the IL-2 Receptor β chain 155 
protein (IL2Rβ) were designed for use in this study. Target-specific RT-qPCR primers were 156 
designed to either span exon-exon boundaries, or to have at least one primer spanning an exon 157 
boundary of the gene of interest. All assay products were visualized on a 3% MetaPhor® 158 
Agarose gel (Lonza) and sequenced to verify the specificity of the assay. Assays for Signal 159 
transducer and activator of transcription 1 (STAT1), MHCIIβ, and Elongation factor 1A 160 
(EF1A) were adapted from previously published studies [24-26]. Efficiency was calculated for 161 
each primer set using triplicates of a five-point, 4 x dilution series of pooled cDNA. EF1A was 162 
used for normalization and is considered the best option of several endogenous reference genes 163 
evaluated for use with Atlantic salmon during SAV infection [27]. All primers and efficiency 164 
data for the assays used in this study are listed in Table 1. 165 
RT-qPCR was run in 384 well plates using Brilliant III Ultra-Fast SYBR® Green master mix 166 
(Agilent) and Applied Biosystems 7900HT Fast Real-Time PCR system in a 7 µL reaction 167 
volume containing 2 µL diluted cDNA and 400 nM of each primer. The running conditions 168 
were as recommended by the manufacturer and a melting curve analysis was included for each 169 
run. The Ct values were normalized using the Ct values from the EF1A assay run on the same 170 
plate for each individual (ΔCt). Fold change (2-ΔΔCt) of transcript level for each individual was 171 
calculated by subtracting the relevant mean ΔCt values obtained from 3 calibrator fish, sampled 172 
before the start of the experiment (Day 0). Outliers were not removed from any of the data sets 173 
for either analysis or presentation in the figures, as they represent the real biological diversity 174 
within these groups.  175 
 176 
2.3 Neutralizing antibody titres to SAV 177 
Blood was collected by caudal vein puncture and plasma was obtained by centrifuging the 178 
blood at 16000 g for 15 min at 4 °C the day of collection. Serum was allowed to clot overnight 179 
and similarly separated the following day. All sera and plasma samples were stored at -80°C 180 
until analysis. Eighteen plasma samples were randomly chosen from all groups in both Phase 181 
A and B and eighteen serum samples were randomly chosen from all groups in Phase B at 21 182 
and 28 dpi (with the exception that all individuals positive for SAV in the BI-B group were 183 
included). Serum samples were only taken from Phase B fish. Neutralizing antibody titres to 184 
SAV were measured by Agri-Food and Biosciences Institute (AFBI) in Belfast (UK) [28]. 185 
 186 
2.4 Data Analysis 187 
The data from RT-qPCR were transformed (+1, log10) and the normal distribution was proved 188 
by Levene’s test employing the Statistica software package. Statistical analysis for 189 
immunological parameters was performed by Graph Pad Prism 6.0 statistical software package. 190 
The statistical significance between groups in Phase A and Phase B and between both phases 191 
was determined using One-way ANOVA on log transformed data followed by Tukey's multiple 192 
comparisons test.  Results showing p < 0.05 are considered significantly different. Although 193 
these methods use averages in their calculations, medians were used for discussion and visual 194 
representation of the data, because of the asymmetric distribution of the data.  195 
Average transcript levels of the genes analysed in positive and negative fish in both infected 196 
groups and in the control group are also included (Supplementary figures S1 and S2). The 197 
statistical significance between control fish and fish either positive or negative for SAV3 RNA 198 
was estimated for each tested gene and also between all sampling time-points and also for both 199 
phases when there was more than one positive or negative fish per sampling time-point (data 200 
not shown).  201 
 202 
3. Results 203 
3.1 SAV3 infection  204 
Two groups of Atlantic salmon post-smolts from the same batch, which were transferred to 205 
seawater 7 weeks apart, were infected with SAV3 by IM or BI. The percentage prevalence at 206 
each time point was determined by analysing the SAV3 RNA in heart tissue [18] (Fig. 1B). 207 
Briefly, at the earliest sampling time-points the fish in the IM-A group had a higher prevalence 208 
of SAV infection and higher viral loads than fish in the BI-A group. By 14 dpi the prevalence 209 
in the IM-A and BI-A groups was 95.8% and 100%, respectively, but viral loads were still 210 
lower in the BI-A group. At later time-points, all the BI-A fish were positive (100% prevalence) 211 
and significantly higher amounts of SAV3 were detected. A maximum of 2 fish were negative 212 
in the IM-A group at the last two sampling time-points. 213 
In Phase B, 95% of the fish in the IM-B group were SAV3 positive at 7 dpi and they remained 214 
almost 100% positive at all later time-points. The viral load in the IM-B group increased up to 215 
14 dpi after which it decreased, falling to levels similar to those seen at 7 dpi levels by 28 dpi. 216 
The BI-B group had only a few positive fish at 14 dpi and this remained the same until the end 217 
of the experiment. At 21 dpi the SAV positive fish in the BI-B group also had relatively low 218 
viral loads. 219 
 220 
3.2 Transcript Profiles of Immune Response Genes 221 
We have performed RT-qPCR on head kidney samples collected at 3, 7, 14, 21, and 28 dpi in 222 
order to study the effect of the extra time in seawater on transcript levels of immune genes 223 
related to cellular, humoral, and inflammatory responses. The reported changes in transcript 224 
levels are from median values calculated for the whole group that comprised 8 fish sampled 225 
from triplicate tanks (altogether 24 individuals per treatment at each sampling time-point). 226 
Many of the changes are heavily influenced by the infection status of the fish since not all fish 227 
exposed to SAV were SAV3- positive at all time-points. Specifically, infected fish in the BI-B 228 
group from Phase B were only found at 14, 21, and 28 dpi. Where these differences between 229 
positive and negative fish are significant, they are mentioned. 230 
 231 
Inflammatory response 232 
Transcript levels of IL-18, IL-10, RIG-1, SOCS1 and STAT1 genes, were also evaluated in 233 
this study to supplement our previous studies describing transcript abundance of other genes 234 
involved in the inflammatory response [23,19]. The mRNA level of pro-inflammatory fish 235 
cytokine IL-18 was down-regulated in all groups in Phase A compared to the calibrator fish 236 
taken before the experiment started. Conversely, in Phase B, IL-18 mRNA levels remained 237 
stable in most individuals throughout the experiment (Fig. 2). Interestingly, a significantly 238 
higher transcript abundance was detected at 7 dpi in SAV3-positive fish in the IM-B group. At 239 
14 dpi some of the individuals from the IM-B group presented a 5- and 17-fold increase when 240 
the median value of the group was 1-fold.  241 
IL-10, an anti-inflammatory cytokine and member of the class II cytokine family, was highly 242 
regulated at 7 and 14 dpi in the IM-A fish, reaching a peak at 7 dpi with 20-fold increases. IL-243 
10 displayed a 5-fold up-regulation in the BI-A group at 14 dpi and it remained significantly 244 
elevated at 21 and 28 dpi. In contrast, IL-10 mRNA levels in fish from the IM-B group only 245 
showed a 4-fold increase at 14 dpi in Phase B and was almost unchanged in the BI-B group at 246 
all time-points (Fig. 2). 247 
The viral RNA sensor, RIG-1, was highly up-regulated in Phase A. In the IM-A group, the 248 
RIG-1 mRNA levels peaked with 17- and 14-fold increases at 7 and 14 dpi, respectively, 249 
followed by a drop at 21 dpi. Fish in the BI-A group also showed significant up-regulation of 250 
RIG-1 transcript levels already at 7 dpi, which peaked with significant 20- and 15-fold 251 
increases at 14 and 21 dpi, respectively. The transcription pattern of RIG-1 was different in 252 
Phase B, where the maximum regulation was seen at 14 dpi in both the IM-B and BI-B groups, 253 
with moderate fold increases of 7.5 and 3, respectively. Furthermore, mRNA levels of RIG-1 254 
had decreased by 28 dpi (Fig. 3). 255 
Similar to RIG-1, the mRNA level of SOCS1 was higher in Phase A than in Phase B, with an 256 
increase for both infected groups at 7, 14 and 21 dpi in Phase A (Fig. 3). In the IM-A group, 257 
SOCS1 transcript levels peaked at 7 dpi but quickly decreased, while the BI-A group peaked 258 
at 14 dpi to a level higher than the IM-A group at 21 dpi. Both returned to control levels at 28 259 
dpi. Fish positive for SAV3 RNA in the IM-A and BI-A groups exhibited higher SOCS1 260 
transcript levels than the negative fish at 7 dpi (S1).  Similarly, in Phase B, positive fish showed 261 
much higher mRNA levels of SOCS1 at 7 and 14 dpi in IM-B and at 14 and 21 dpi in BI-B 262 
relative to the negative fish at the same time-points (S2). 263 
STAT1 had a similar pattern of modulation to SOCS1 with both the IM-A and BI-A groups 264 
showing increases, while in Phase B, only the IM-B group had significant fold increases (Fig. 265 
3). However, the same positive individuals exhibiting elevated fold increases of SOCS1 also 266 
had high fold increases of STAT1 (S1 and S2). 267 
 268 
Cellular response 269 
The regulation of CD40, CD8, CD4-1, MHCIIβ, NFκB, IL-2Rβ, IL-2 and IL-15 genes was 270 
measured in an effort to evaluate cellular immune responses during the experiment. The level 271 
of the costimulatory molecule CD40 mRNA was up-regulated in both the IM and BI groups in 272 
Phase A and B. The highest fold change in the IM-A and BI-A groups, corresponding to a 2-273 
fold up-regulation compared to the control group, and was observed at 21 dpi. Interestingly, at 274 
21 dpi, two negative individuals in the IM-A group showed more than a 7-fold increase when 275 
the median value in the IM-A group was 2-fold. Approximately 2-fold increases were apparent 276 
in the IM-B and BI-B groups at 14 dpi, one week earlier than groups in Phase A (Fig. 4). CD40 277 
mRNA levels in the IM-A, BI-A and IM-B groups reached a peak at 21 dpi and the BI-B group 278 
showed only a moderate increase during the course of the experiment. SAV-positive fish had 279 
a higher average value of CD40 mRNA abundance than SAV-negative fish in the IM-A and 280 
IM-B groups at 7 and 3 dpi, respectively.  281 
The T cell co-receptors, CD4-1 and CD8, were relatively unchanged showing a slight down-282 
regulation in all groups (Fig. 4). CD4-1 transcript abundance in Phase A was slightly 283 
downregulated at 7 dpi, but by 28 dpi it had increased 2-3-fold in all groups. A different CD4-284 
1 transcription pattern was observed in infected groups in Phase B where the basal mRNA level 285 
was lower than in Phase A and unchanged throughout the sampling period. (Fig. 4). In the IM-286 
B group at 3 dpi, three SAV-positive individuals showed more than a 4-fold increase, while in 287 
the BI-B group two negative individuals showed 2- and 4-fold increases, when the median 288 
value in both groups was 1-fold (S2 and Fig 4).  289 
Differences in median values of the CD8α transcript levels between infected groups and control 290 
groups in Phase A and B were small, but there was a slight downward regulation in Phase A. 291 
Whereas in Phase B transcripts were stable throughout the sampling period (Fig. 4). 292 
Interestingly, some of the individuals from the IM-A and BI-A groups, which had high 293 
transcript levels of CD8α at 21 and 28 dpi, also showed elevated levels of CD40 and CD4-1. 294 
The MHCIIβ gene regulation pattern was different in Phase A and B for both infected groups 295 
compared to their respective controls (Fig. 5). MHCIIβ was relatively unchanged in Phase A. 296 
The IM-B group showed a significant increase in MHCIIβ mRNA levels at 14  and 21 dpi, 297 
corresponding to a doubling compared to the control group, followed by a decrease at 28 dpi. 298 
Moreover, the basal mRNA levels of the MHCIIβ was higher in the CT-B group than in the 299 
CT-A group significantly so at 14 dpi (S3). 300 
NFκB mRNA abundance was slightly up-regulated in both infected groups in Phase A whereas 301 
in Phase B transcript levels were stable. In Phase A, the median value of each group at all time-302 
points was mostly higher than in Phase B, when the IM-A group was elevated over 2-fold at 303 
21 and 28 dpi. In Phase B, both infected groups were highest at 14 dpi but decreased to control 304 
values at 28 dpi (Fig. 5). 305 
The IL-2Rβ gene encodes a cytokine receptor protein that interacts specifically with IL-2.  IL-306 
2Rβ transcript levels were rapidly up-regulated after SAV3 infection, as indicated by the 307 
detection of elevated levels in both infected groups in both phases at 3 dpi (Fig. 5). These 308 
changes in transcript levels were accompanied by changes in the control groups resulting in 309 
significantly lower fold changes in the BI-A group at 28 dpi, when both the IM-A and CT-A 310 
groups showed over 2-fold increases.  311 
The members of the IL-2 subfamily of cytokines, namely IL-2 and IL-15, was also analysed 312 
(Fig. 6).  IL-2 mRNA level was regulated to only a small extent in both phases, while IL-15 313 
mRNA abundance was unchanged in Phase A, except a 2-fold increase at 14 dpi in the IM-B 314 
group. Interestingly, the lower expression of IL-2 mRNA in the BI-A group at 28 dpi was 315 
reflected in the lower expression of its receptor, IL-2Rβ, at the same time-point. 316 
 317 
Humoral response 318 
Both IgM and IgT mRNA levels were up-regulated during the experiment, but a week later in 319 
Phase A compared to Phase B (Fig. 7). In Phase A, both infected groups exhibited the similar 320 
median value of IgM and IgT mRNA abundance and both were upregulated at 21 and 28 dpi. 321 
In the IM-B group, IgM and IgT transcript levels reached a peak at 14 and 21 dpi respectively, 322 
and a trend of down-regulation at 28 dpi could be seen. IgM mRNA was only up-regulated in 323 
SAV-positive fish in the BI-B group and 5 of 7 positive individuals showed ≥4-fold (4, 4, 4, 5, 324 
9) increase at 28 dpi (S2). Moreover, IgT transcript levels in the BI-B group were also higher 325 
in SAV-positive fish relative to SAV-negative fish at 21 and 28 dpi, and such differences were 326 
statistically significant (S2). 327 
 328 
3.3 Differences between control fish in both phases 329 
We found differences in the basal transcript level in some of the analysed genes between the 330 
CT-A and CT-B groups (Table 2 and S3). CD40, CD4-1, CD8α, and SOCS1 were more 331 
abundantly regulated in the CT-A than in the CT-B, and the differences were significantly 332 
higher at 3 and 28 dpi (Table 2 and S3). The basal transcript level of NFκB, IL-15, and RIG-1 333 
were also significantly higher in the CT-A group, but only at 28 dpi. In contrast, other genes 334 
showed a higher expression in the CT-B group compared to the CT-A group, as seen with the 335 
MHCIIβ at 14 dpi, IgM at 7 and 14 dpi, and the IL-18 with a peak at 7 dpi.  336 
 337 
3.4 Neutralizing antibody titres 338 
Plasma and serum samples collected at 21 and 28 dpi were assayed for the presence of SAV-339 
neutralizing antibodies. In Phase A, the fish had no detectable neutralizing antibodies neither 340 
at 21 nor at 28 dpi.  341 
Neutralizing antibodies were not detected in the plasma samples from the control fish nor in 342 
those from any of the infected groups at 21 dpi in Phase B. At 28 dpi 67% (12 of 18) of the 343 
IM-B group and 11% (2 of 18) of the BI-B group plasma samples had neutralizing antibodies 344 
at detectable titres. All individuals showing an antibody response were positive for SAV RNA 345 
and in the BI-B group both SAV-positive fish with neutralizing antibodies had titres of ≥1:40 346 
(Fig. 8). Similarly, in the serum samples, 17% (3 of 18) of the IM-B group at 21 dpi, 77% (14 347 
of 18) of the IM-B group at 28 dpi and 22% (4 of 18) of the BI-B group at 28 dpi had 348 
neutralizing antibodies (Table 3). 349 
  350 
4. Discussion 351 
The salmon farming industry suffers huge economic losses due to PD outbreaks every year. 352 
Despite the use of vaccines against SAV by some of the farms, PD is still regularly observed 353 
during the grow-out phase in seawater. Although several studies have examined immune 354 
responses to SAV in Atlantic salmon, most of the mechanisms leading to protection still remain 355 
unclear. Therefore, the identification of measures that can potentially prevent or at least reduce 356 
SAV infection after seawater transfer is of particular interest. Thus, in this study, we have used 357 
our recently described BI challenge model to examine the relative regulation of genes involved 358 
in innate and adaptive responses to virus infection [23,19]. Taken together with previous 359 
studies from our laboratory, the results described here give a more detailed understanding of 360 
the differences in the anti-viral immune responses that develop in fish from the same 361 
production batch that are infected with SAV at either 2 or 9 weeks after seawater transfer. 362 
RIG-1 is a pattern recognition receptor (PRR) that interacts with dsRNA leading to the 363 
production of type I interferons (IFNs) and the expression of IFN-stimulated genes (ISGs) [29]. 364 
RIG-1 showed similar patterns of transcription as another PRR, LGP2a, in Phase A and B 365 
[19,23]. Both PRRs were highly up-regulated in both phases and the up-regulation in phase A 366 
was greater. Moreover, RIG-1 was one of the most highly constitutively expressed immune 367 
gene examined in this study.  368 
IL-10 is a member of the class II cytokine family that inhibits the activity of Th1 cells, natural 369 
killer cells, and macrophages. It has been demonstrated that it plays an important role in both 370 
the earliest and later anti-inflammatory responses to SAV3 infection [16]. In this study, we 371 
analysed the regulation of IL-10 gene until 4 wpi and up-regulation at 7 dpi in the IM-A group 372 
and at 14 dpi in the BI-A, IM-B, and BI-B groups could be observed. Whereas, the pro-373 
inflammatory fish cytokine, IL-18, which induces IFN-γ production and promotes Th1 374 
immunity in vertebrates [30] was relatively unchanged in both phases during the whole 375 
experiment. 376 
STAT1 and SOCS1 are an activator and an inhibitor of the JAK/STAT signaling pathway, 377 
respectively, furthermore, both are crucially involved in the control of inflammatory responses. 378 
Both genes showed a high level of mRNAs at 7 dpi in all infected groups and had similar 379 
profiles of expression in Phase A and B, suggesting that they are regulating each other. The 380 
upregulation in the BI-A group, although lower, was maintained for a longer time compared to 381 
the IM-A group. This pattern of expression was similar to that which was observed for a 382 
number of other innate immune genes in this group of fish after SAV infection [23]. The high 383 
transcript abundance of SOCS1 has been suggested to be a consequence of SAV infection and 384 
may be a survival strategy for the virus. Increasing SOCS1 mRNA expression may 385 
subsequently inhibit signal transduction via the JAK/STAT pathway and may contribute to 386 
viral replication [31,32]. In our previous study, we observed a reduction in ISG and Mx 387 
expression in the IM-B group [19] that partially may be due to up-regulation of the SOCS1 388 
after SAV infection.  389 
Regulation of IL-10, RIG-1, SOCS1, and STAT-1 genes in Phase A for both challenge models 390 
(represented by trend-lines on the figures) was consistent with our previous results on the innate 391 
immune genes associated with the IFN response or with inflammation [23]. Expression of these 392 
transcripts was higher in head kidney samples from Phase A relative to Phase B, which 393 
suggested a greater inflammatory response in Phase A. Interestingly, an abundance of 394 
inflammatory cells was observed as early as 7 dpi in SAV3 target-organs (pancreas and heart) 395 
in Phase B post-smolts, indicating activation of a cellular immune response to SAV3, which 396 
was not observed in Phase A fish [18]. Furthermore, the regulation of the genes mentioned 397 
above, and also of IgT and CD40, was delayed by one week in the BI-A fish when compared 398 
to the IM-A fish. This suggests that, in the BI group, the immune response to SAV3 was 399 
delayed in comparison to the IM infection, probably due to the infection route and/or the 400 
reduced viral dose.  401 
Most of the adaptive immune genes studied here did not change significantly during the 402 
experimental period. However, the accumulative effect of many small changes in the transcript 403 
level of several genes in the same signaling pathway may produce biological effects. This is 404 
illustrated by the slight up-regulation in both IM-A and CT-A at 28 dpi in several genes all 405 
involved in cellular immunity; CD40, CD4-1, CD8 α, IL-2, IL2Rβ and IL-15 when the BI-A 406 
group showed no change at this time-point. Furthermore, IgT and IgM mRNA transcript levels 407 
were seen to be higher in fish that also showed a high expression of CD40, CD4-1 and CD8α 408 
mRNA. 409 
Also, of these genes the T-cell co-receptors genes, CD4-1 and CD8α, were not significantly 410 
up-regulated during this study at any time-point in any of the groups, suggesting that the T cell 411 
response was not induced in response to SAV3 infection, at least in the first 4 weeks after 412 
infection. This is consistent with previous results showing that up-regulation of CD4-1 and 413 
CD8α was not detected at the earlier time points in co-habitation trials. However, both genes 414 
were found to be significantly expressed at 6 and 8 weeks post-infection [33,16,17]. On the 415 
other hand, we detected high mRNA levels of MHCIIβ, CD40, and IL-15 in head kidney 416 
samples from the IM-B group, which are indicative of activation of a more cell-mediated 417 
immune response. MHCIIβ is a part of the MHCII complex, which is involved in antigen 418 
presentation and is normally expressed on antigen-presenting cells. Its expression was 419 
significantly up-regulated at 14 and 21 dpi in the IM-B group, in contrast to previous studies 420 
where regulation of MHCII mRNAs was only detected after 8 weeks in target organs during 421 
SAV3 co-habitation infection [16,33]. A similar observation of later/delayed response of 422 
MHCII expression was reported after infection with ISAV [34]. In addition, the costimulatory 423 
molecule CD40, a transmembrane glycoprotein, which is a member of the tumor necrosis factor 424 
(TNF) receptor superfamily and plays an immune-regulatory function in the adaptive response 425 
[35], was studied. CD40 was up-regulated at 7 dpi in both, the IM-A and IM-B groups, and this 426 
up-regulation was maintained for a longer time in the IM-B group. Furthermore, the cytokine 427 
IL-15, which is induced by IFN-γ in salmon leucocytes and plays a role in promoting Th1 428 
responses and memory T cell maturation, was significantly up-regulated in the IM-B group at 429 
14 dpi [36]. We also observed that IgM and IgT were highly up-regulated in the IM-B group. 430 
Previously our lab has shown that higher numbers of IgM+ and MHC II+ cells could be detected 431 
by immune-histo-chemical staining of the heart and pancreas of IM-B fish [37]. Taken together 432 
with findings presented here, this suggests that a larger population of B cells was present in the 433 
head kidney in the IM-B group. 434 
Increased regulation of IgM and IgT genes was especially interesting since we were able to 435 
link gene expression data with the presence or absence of SAV neutralizing antibodies in 436 
individual fish. A neutralizing antibody response was clearly detected in Phase B, where only 437 
moderate increases (3-4-fold) in gene expression levels led to high titres of neutralizing 438 
antibodies. The plasma results show a lack of a neutralizing antibody response after only 2 439 
weeks in seawater compared to the Phase B fish. Besides, many plasma samples from Phase A 440 
fish displayed a toxic reaction to the CHSE-214 cell line used in the neutralization assay, which 441 
was not seen with any of the Phase B samples. In addition, the serum results from Phase B fish 442 
support the high titres observed in plasma samples and appear more sensitive with both 443 
detectable antibodies at 21 dpi and more SAV3-positive individuals. Three of the 4 BI-B fish 444 
with detectable neutralizing antibodies were also shown to be SAV-positive and had a high 445 
abundance of IgM mRNA (3.9-, 4- and 4.7-fold change). The results from the BI-B group are 446 
more difficult to interpret due to the lower dose of virus present in the shedder water and the 447 
lower prevalence of SAV positive fish detected in this group. Interestingly, very little 448 
pancreatic pathology was observed in two of these fish, perhaps indicating that the immune 449 
response, especially the antibody response had successfully cleared the virus. The apparent 450 
lack of an antibody response in Phase A may be explained by the ability of the SAV nsP2 451 
protein to suppress the host antiviral response and shut-off protein expression [38-40]. This 452 
ability may be one of the factors that contribute to the poor immune response seen during SAV 453 
infection in Phase A, despite the elevated abundance of several genes in fish recently 454 
transferred to seawater. Thus, we can speculate that although the basal expression of some of 455 
the genes studied was found to be greater in CT-A than in CT-B, fish from Phase B were able 456 
to mount a more effective response that could have inhibited the SAV mediated host-shut-off 457 
protein mechanism. Conversely, many innate immune genes were more highly expressed in 458 
Phase B [19], but it is quite possible that the timely production of neutralizing antibodies is 459 
decisive in mitigating SAV3 infection since previous studies have shown antibodies to both 460 
neutralize SAV and protect against infection [41]. On the other hand, inflammatory cells and 461 
MHC class II+ and IgM+ cells were observed in a greater number in the target organs in the 462 
CT-B group [16,37]. 463 
 464 
In conclusion, Atlantic salmon post-smolts transferred to seawater at the same time, and 465 
challenged at week 2 and 9, 7 weeks apart, displayed very different immune responses 466 
following infection with SAV3. Fish adapted to seawater for an extra 7 weeks appeared to have 467 
a better developed and more effective cell-mediated and humoral response against SAV3 468 
infection, resulting in only mild histopathological changes in the pancreas and heart, and a 469 
reduced susceptibility to SAV3 infection. 470 
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BI bath immersion 479 
cDNA complementary DNA 480 
Dpi Days post infection 481 
IFN interferon 482 
IL Interleukin 483 
IM Intramuscular injection 484 
ISGs interferon-stimulated genes 485 
MHCIIβ Major Histocompatibility Complex class II beta chain  486 
NFκB Nuclear factor kappa-light-chain-enhancer of activated B 487 
RIG-1 Retinoic-acid-inducible protein 1 488 
RT-qPCR reverse transcriptase quantitative polymerase chain reaction 489 
SOCS1 Suppressor of cytokine signaling 1 490 
SWT seawater transfer 491 
TCID50 50% tissue culture infective dose 492 
TCR T cell receptor 493 
wpt weeks post seawater transfer 494 
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 503 
Highlights 504 
• Neutralizing abs to SAV were detected only in salmon adapted for longer to seawater. 505 
• Salmon adapted for longer to SW develop stronger cell-mediated immunity to SAV. 506 
• Upon shorter adaptation to SW, salmon show IL-10 upregulation at early time points. 507 
• SOCS1 gene was upregulated in all infected groups in both phases. 508 
• Upon shorter adaptation to SW, SOCS1 upregulation was maintained for longer time. 509 
 510 
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Figure legends 636 
Fig. 1. Experimental setup and percentage prevalence of SAV-positive hearts.  637 
A. Atlantic salmon post- smolts 2 weeks (Phase A) or 9 weeks (Phase B) post seawater-transfer 638 
(wpt) were infected with SAV3. Treatments performed in triplicate tanks consisted of 639 
intramuscular (i.m.) injection with non-infected cell culture supernatant (CT group), with 104 640 
TCID50 SAV3 (IM group), and bath challenge in water containing shed virus (BI group). 641 
Shedder fish were i.m. injected with SAV3 approx. 1 week before the day of experimental 642 
challenge. 8 fish per tank (24 fish per treatment group) were collected at each sampling time-643 
point: 3, 7, 14, 21 and 28 days post-infection (dpi). B. Bars represent mean percentage of 644 
SAV3-RNA positive samples ± SEM at each time point of the IM-A (black bars), IM-B (dark 645 
grey bars), BI-A (white bars) and BI-B (light grey bars) groups. N=24 for all groups and time-646 
points (except for the BI-A group at 14 dpi where n=22 and the IM-B group at 7 and 28 dpi 647 
where n = 22 and 23 respectively). 648 
 649 
Fig. 2. Fold change in mRNA levels of IL-18 and IL-10.  650 
The y axis represents normalized, fold changes in mRNA levels for each treatment group 651 
compared to calibrator fish sampled before day 0. Boxes represent the 25th and 75th percentiles 652 
for each group with the median value shown by a black bar within each box. The whiskers 653 
represent the maximum and minimum values for each group. Open bars represent the CT 654 
group, dark grey bars the IM group and light grey bars the BI group. The left panels correspond 655 
to the Phase A and the right panels correspond to the Phase B groups. Trend lines indicate 656 
transcriptional changes over time; solid line IM group and dashed line the BI group. Asterisks 657 
denote statistically significant differences between the infected and CT groups: * p < 0.05, ** 658 
p < 0.01 and *** p < 0.001. Lower case letters indicate statistically significant differences 659 
between the IM and BI groups: a p < 0.05, b p < 0.01 and c p < 0.001. 660 
 661 
Fig. 3. Fold change in mRNA levels of RIG-1, SOCS1, and STAT1.  662 
The y axis represents normalized, fold changes in mRNA levels for each treatment group 663 
compared to calibrator fish sampled before day 0. Boxes represent the 25th and 75th percentiles 664 
for each group with the median value shown by a black bar within each box. The whiskers 665 
represent the maximum and minimum values for each group. Open bars represent the CT 666 
group, dark grey bars the IM group and light grey bars the BI group. The left panels correspond 667 
to the Phase A and the right panels correspond to the Phase B groups. Trend lines indicate 668 
transcriptional changes over time; solid line IM group and dashed line the BI group. Asterisks 669 
denote statistically significant differences between the infected and CT groups: * p < 0.05, ** 670 
p < 0.01 and *** p < 0.001. Lower case letters indicate statistically significant differences 671 
between the IM and BI groups: a p < 0.05, b p < 0.01 and c p < 0.001. 672 
 673 
Fig. 4. Fold change in mRNA levels of CD40, CD4-1, and CD8α. 674 
The y axis represents normalized, fold changes in mRNA levels for each treatment group 675 
compared to calibrator fish sampled before day 0. Boxes represent the 25th and 75th percentiles 676 
for each group with the median value shown by a black bar within each box. The whiskers 677 
represent the maximum and minimum values for each group. Open bars represent the CT 678 
group, dark grey bars the IM group and light grey bars the BI group The left panels correspond 679 
to the Phase A and the right panels correspond to the Phase B groups. Trend lines indicate 680 
transcriptional changes over time; solid line IM group and dashed line the BI group. Asterisks 681 
denote statistically significant differences between the infected and CT groups: * p < 0.05, ** 682 
p < 0.01 and *** p < 0.001. Lower case letters indicate statistically significant differences 683 
between the IM and BI groups: a p < 0.05, b p < 0.01 and c p < 0.001. 684 
 685 
Fig. 5. Fold change in mRNA levels of MHCIIβ, NFκB, and IL-2Rβ.  686 
The y axis represents normalized, fold changes in mRNA levels for each treatment group 687 
compared to calibrator fish sampled before day 0. Boxes represent the 25th and 75th percentiles 688 
for each group with the median value shown by a black bar within each box. The whiskers 689 
represent the maximum and minimum values for each group. Open bars represent the CT 690 
group, dark grey bars the IM group and light grey bars the BI group. The left panels correspond 691 
to the Phase A and the right panels correspond to the Phase B groups. Trend lines indicate 692 
transcriptional changes over time; solid line IM group and dashed line the BI group. Asterisks 693 
denote statistically significant differences between the infected and CT groups: * p < 0.05, ** 694 
p < 0.01 and *** p < 0.001. Lower case letters indicate statistically significant differences 695 
between the IM and BI groups: a p < 0.05, b p < 0.01 and c p < 0.001. 696 
 697 
Fig. 6. Fold change in mRNA levels of IL-2 and IL-15.  698 
The y axis represents normalized, foldchanges in mRNA levels for each treatment group 699 
compared to calibrator fish sampled before day 0. Boxes represent the 25th and 75th percentiles 700 
for each group with the median value shown by a black bar within each box. The whiskers 701 
represent the maximum and minimum values for each group. Open bars represent the CT 702 
group, dark grey bars the IM group and light grey bars the BI group. The left panels correspond 703 
to the Phase A and the right panels correspond to the Phase B groups. Trend lines indicate 704 
transcriptional changes over time; solid line IM group and dashed line the BI group. Asterisks 705 
denote statistically significant differences between the infected and CT groups: * p < 0.05, ** 706 
p < 0.01 and *** p < 0.001. Lower case letters indicate statistically significant differences 707 
between the IM and BI groups: a p < 0.05, b p < 0.01 and c p < 0.001. 708 
 709 
Fig. 7. Fold changes in mRNA levels of IgM and IgT.  710 
The y axis represents normalized, fold changes in mRNA levels for each treatment group 711 
compared to calibrator fish sampled before day 0. Boxes represent the 25th and 75th percentiles 712 
for each group with the median value shown by a black bar within each box. The whiskers 713 
represent the maximum and minimum values for each group. Open bars represent the CT 714 
group, dark grey bars the IM group and light grey bars the BI group. The left panels correspond 715 
to the Phase A and the right panels correspond to the Phase B groups. Trend lines indicate 716 
transcriptional changes over time; solid line IM group and dashed line the BI group. Asterisks 717 
denote statistically significant differences between the infected and CT groups: * p < 0.05, ** 718 
p < 0.01 and *** p < 0.001. Lower case letters indicate statistically significant differences 719 
between the IM and BI groups: a p < 0.05, b p < 0.01 and c p < 0.001. 720 
 721 
Fig. 8. Neutralizing antibody titres to SAV at 28 dpi in fish from Phase B groups. 722 
 Percentage of fish producing neutralizing antibodies to SAV in plasma samples at 28 dpi. Grey 723 
bars represent the i.m. injected group (IM-B) and black bars represent the bath challenged 724 
group (BI-B). 725 
 726 
Table 1.  Primer sequences. Primers employed in this study, product size, relative efficiencies 727 
and the Genbank accession numbers used for primer design or the reference for previously 728 
published assays. 729 
 730 
Table 2. Significant differences (ANOVA on log transformed data followed by Tukey's 731 
multiple comparisons test) in gene expression at all time-points and for all genes 732 
comparing Phase A to Phase B. * p < 0.05, ** p < 0.01 and *** p < 0.001. 733 
 734 
Table 3. Neutralizing antibody titres. Number of fish with neutralizing antibodies in plasma 735 
and serum samples in fish from Phase B groups. 736 
 737 
S1. Immune gene mRNA levels in control, positive and negative fish for SAV3-RNA in 738 
Phase A. Graphs show trend lines between average fold change ± SEM positive IM-A (light 739 
blue) and BI-A (yellow) and negative IM-A (dark blue), BI-A (red) and CT-A (black) groups 740 
for all genes analysed. 741 
 742 
S2. Immune gene mRNA levels in control, positive and negative fish for SAV3-RNA in 743 
Phase B. Graphs show trend lines between average fold change ± SEM positive IM-A (light 744 
blue) and BI-A (yellow) and negative IM-A (dark blue), BI-A (red) and CT-A (black) groups 745 
for all genes analysed. 746 
 747 
S3. Fold changes in mRNA levels between control fish in both phases. 748 
The y axis represents normalized, fold changes in mRNA levels for each treatment group 749 
compared to calibrator fish sampled before day 0. Boxes represent the 25th and 75th percentiles 750 
for each group with the median value shown by a black bar within each box. The whiskers 751 
represent the maximum and minimum values for each group. Dark grey bars represent the CT-752 
A group and light grey bars the CT-B group. Trend lines indicate transcriptional changes over 753 
time; solid line CT-A group and dashed line the CT-B group. Asterisks denote significant 754 
differences between the CT groups: * p < 0.05, ** p < 0.01 and *** p < 0.001.  755 
  756 
Table 1 757 
*bps = base pairs 758 
  759 
Gene Primers sequences Efficiency Product size 
bps* 
References/Genbank 
accession No. 
CD40 Fwd: GCCCTGCCAAGAGGATGA 
Rv: GTCAGGCACTCTTTACTGGAACA 
2,06 173 NM_0011412361 
STAT1 Fwd: TGTCTGTTGGCTCAGTTGCG 
Rv: GAAATTGATGCTGTGGCGTCT 
1,92 100 [24] / NM_001123654.1 
SOCS1 Fwd: CATTCCGCTGCCAAGTAGAC 
Rv: CCGTGGCGACGTCCTT 
1,95 
 
127 
 
KF699315 
MHCII Fwd: CTCACTGAGCCCATGGTGTAT 
Rv: GAGTCCTGCCAAGGCTAAGATG 
1,90 117 [25] / BT060311 
EF1A Fwd: CCCCTCCAGGACGTTTACAAA 
Rv: CACACGGCCCACAGGTACA 
2,02 
 
57 [26] / BG936182.1 
CD8α Fwd: CTTCAGCGAGGAGCAGATAAAC 
Rv: GGCTGTGGTCATTGGTGTAGTC 
2,04 187 NM_001123583.1 
CD4-1 Fwd: GTGGAGGTGCTACAGGTGTTTTC 
Rv: GGGGAGGAGCCTAAAGCG 
2,00 158 EU409794.1 
RIG-1 Fwd: CCTCTGCTACAGGAGCCAATA 
Rv: GCCGGTTGGTGCACAGAT 
1,95 157 NM_001163699.1 
NFκB Fwd: GCACTACCATTTTACTGACGCA 
Rv: GCGTTGGGTGACTTGCTGT 
2,07 188 NM_001173583.1 
IL-18 Fwd: GAGCAATGCAAAGCAGATGATT 
Rv: GCTCCAGTGGTTTGGCAGAA 
2,07 177 BT125392.1 
IL-15 Fwd: GCTTCTTAATATTGAGCTGCCTGA 
Rv: GGCATCTGATTTTTCTATGGTACTT 
2,04 146 NM_001279065.1 
IL-2 Fwd: GCGGATGTAGAGAAAAGCATTG 
Rv: CATTCTGACGAGTCCGTTCTGAT 
2,32 155 HE805272.1 
IL-10 Fwd: GCTATGGACAGCATCCTGAAGTT 
Rv: GGTTGTTCTGCGTTCTGTTGTT 
1,99 76 EF165028 
 
IL-2Rβ Fwd: CTCCAAGGACTGTTTTGTGTGAA 
Rv: GAGGTGCTCGGCTGAACTGA 
1,95 242 NM_001140548.1 
IgM Fwd: CCAGTGAAGAAACAAGCGGAAT 
Rv: CCTCATCCATTTGATTGTGTGTGTA 
2,02 157 
 
S48652 
IgT Fwd: CAACAAAGTCACTGTCACCTGGAA 
Rv: CCGTCAGCGGTTCTGTTTTG 
2,10 212 GQ907003.1 
Table 2 
  
3 dpi 7 dpi 14 dpi 21 dpi 28 dpi 
 
Gene 
Assay 
Treatment CT-B IM-B BI-B CT-B IM-B BI-B CT-B IM-B BI-B CT-B IM-B BI-B CT-B IM-B BI-B 
CD40 CT-A * * **     ***     *   
IM-A    *    *     *   
BI-A            **    
CD4-1  CT-A *** * **          *** *** *** 
IM-A **  *       * * * *** *** *** 
BI-A *      * * ** ** *** *** *** *** *** 
CD8  CT-A ** * *          *** ** ** 
IM-A *            ***  * 
BI-A                
MHCII  CT-A     ** * *** *** ***  ***    * 
IM-A    * *** ** ** *** **  ***   * ** 
BI-A     *  ** *** **  ***   * ** 
NFκβ  CT-A             ** * * 
IM-A *          * ** ** * * 
BI-A    *  * **    * **    
IL-2R CT-A               * 
IM-A                
BI-A                
IgM CT-A    ** *** *** ** *** **  ***     
IM-A    * *** **  *** *** ** ***  ***   
BI-A     *** **  ***  **  *** **   
IgT  CT-A     **   ***        
IM-A          *** ** ***    
BI-A     **     ***  ***    
IL-2  CT-A               * 
IM-A                
BI-A                
IL-10 CT-A        *** **       
IM-A    *** *** *** *         
BI-A       ***   *** ** *** *   
IL-15 CT-A        ***     *** * ** 
IM-A        ***     *   
BI-A        *        
IL-18 CT-A    *    ***        
IM-A    *** ** **  ***        
BI-A    **    ***        
RIG-1 CT-A     ** *  ***   **  *** *** *** 
IM-A    *** *** *** ***  *** ** *** *** *** *** *** 
BI-A    **   ***  *** *** *** *** *** *** *** 
SOCS1 CT-A * *** ***     ***     *** *** *** 
IM-A  * ** *** ** *** *** * *** ** ***  *** *** ** 
BI-A   * ***  ** *** *** *** *** *** *** *** *** *** 
STAT1 CT-A     ***   ***        
IM-A    ***  *          
BI-A       *   *** *** ***    
 
  
 
 
 
Table 3 
  Titre  
Group Sample 1:20 1:30 1:40 <1:40 Total 
IM-B 21 dpi Plasma     0 
Sera 2 1   3 
BI-B 21 dpi Plasma     0 
Sera     0 
IM-B 28 dpi Plasma 2 3 3 4 12 
Sera 2 4 3 5 14 
BI-B 28 dpi Plasma   1 1 2 
Sera  3  1 4 

  
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
  
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
